Engineering nanoparticles for targeting rheumatoid arthritis: Past, present, and future trends
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/1822/56681 |
Resumo: | Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial joint inflammation and cartilage and bone tissue destruction. Although there exist some treatment strategies for RA, they are not completely safe and effective. Therefore, it is important to develop and test new drugs for RA that specifically target inflamed/swollen joints and simultaneously attenuate other possible damages to healthy tissues. Nanotechnology can be a good alternative to consider when envisioning precise medication for treating RA. Through the use of nanoparticles, it is possible to increase bioavailability and bioactivity of therapeutics and enable selective targeting to damaged joints. Herein, recent studies using nanoparticles for the treatment of RA, namely with liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles, have been reviewed. These therapeutic strategies have shown great promise in improving the treatment over that by traditional drugs. The results of these studies confirm that feasibility of the use of nanoparticles is mainly due to their biocompatibility, low toxicity, controlled release, and selective drug delivery to inflamed tissues in animal RA models. Therefore, it is possible to claim that nanotechnology will, in the near future, play a crucial role in advanced treatments and patient-specific therapies for human diseases such as RA. |
id |
RCAP_4733a970b6bbec857cd33cb49c6ecff6 |
---|---|
oai_identifier_str |
oai:repositorium.sdum.uminho.pt:1822/56681 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Engineering nanoparticles for targeting rheumatoid arthritis: Past, present, and future trendsDendrimersLiposomesNanoparticlesRheumatoid arthritisCiências Médicas::Biotecnologia MédicaScience & TechnologyRheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial joint inflammation and cartilage and bone tissue destruction. Although there exist some treatment strategies for RA, they are not completely safe and effective. Therefore, it is important to develop and test new drugs for RA that specifically target inflamed/swollen joints and simultaneously attenuate other possible damages to healthy tissues. Nanotechnology can be a good alternative to consider when envisioning precise medication for treating RA. Through the use of nanoparticles, it is possible to increase bioavailability and bioactivity of therapeutics and enable selective targeting to damaged joints. Herein, recent studies using nanoparticles for the treatment of RA, namely with liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles, have been reviewed. These therapeutic strategies have shown great promise in improving the treatment over that by traditional drugs. The results of these studies confirm that feasibility of the use of nanoparticles is mainly due to their biocompatibility, low toxicity, controlled release, and selective drug delivery to inflamed tissues in animal RA models. Therefore, it is possible to claim that nanotechnology will, in the near future, play a crucial role in advanced treatments and patient-specific therapies for human diseases such as RA.Financial support under the ARTICULATE project (No. QREN-13/SI/2011-23189). This study was also funded by the Portuguese Foundation for Science and Technology (FCT) project OsteoCart (No. PTDC/CTM-BPC/115977/2009), as well as the European Union’s FP7 Programme under grant agreement no REGPOT-CT2012-316331-POLARIS. The FCT distinction attributed to J. M. O. under the Investigator FCT program (No. IF/00423/2012) is also greatly acknowledged. C. G. also wished to acknowledge FCT for supporting her research (No. SFRH/BPD/94277/2013)info:eu-repo/semantics/publishedVersionTsinghua University PressUniversidade do MinhoOliveira, Isabel Maria Lopes MatosGonçalves, C.Reis, R. L.Oliveira, J. M.2018-042018-04-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/56681engOliveira I. M., Gonçalves C., Reis R. L., Oliveira J. M. Engineering nanoparticles for targeting rheumatoidarthritis: Past, present, and future trends, Nano Research, Vol. 11, Issue 9, pp. 1-18, doi:10.1007/s12274-018-2071-3, 20181998-012410.1007/s12274-018-2071-3https://link.springer.com/article/10.1007%2Fs12274-018-2071-3info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:22:19Zoai:repositorium.sdum.uminho.pt:1822/56681Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:15:47.761772Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Engineering nanoparticles for targeting rheumatoid arthritis: Past, present, and future trends |
title |
Engineering nanoparticles for targeting rheumatoid arthritis: Past, present, and future trends |
spellingShingle |
Engineering nanoparticles for targeting rheumatoid arthritis: Past, present, and future trends Oliveira, Isabel Maria Lopes Matos Dendrimers Liposomes Nanoparticles Rheumatoid arthritis Ciências Médicas::Biotecnologia Médica Science & Technology |
title_short |
Engineering nanoparticles for targeting rheumatoid arthritis: Past, present, and future trends |
title_full |
Engineering nanoparticles for targeting rheumatoid arthritis: Past, present, and future trends |
title_fullStr |
Engineering nanoparticles for targeting rheumatoid arthritis: Past, present, and future trends |
title_full_unstemmed |
Engineering nanoparticles for targeting rheumatoid arthritis: Past, present, and future trends |
title_sort |
Engineering nanoparticles for targeting rheumatoid arthritis: Past, present, and future trends |
author |
Oliveira, Isabel Maria Lopes Matos |
author_facet |
Oliveira, Isabel Maria Lopes Matos Gonçalves, C. Reis, R. L. Oliveira, J. M. |
author_role |
author |
author2 |
Gonçalves, C. Reis, R. L. Oliveira, J. M. |
author2_role |
author author author |
dc.contributor.none.fl_str_mv |
Universidade do Minho |
dc.contributor.author.fl_str_mv |
Oliveira, Isabel Maria Lopes Matos Gonçalves, C. Reis, R. L. Oliveira, J. M. |
dc.subject.por.fl_str_mv |
Dendrimers Liposomes Nanoparticles Rheumatoid arthritis Ciências Médicas::Biotecnologia Médica Science & Technology |
topic |
Dendrimers Liposomes Nanoparticles Rheumatoid arthritis Ciências Médicas::Biotecnologia Médica Science & Technology |
description |
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial joint inflammation and cartilage and bone tissue destruction. Although there exist some treatment strategies for RA, they are not completely safe and effective. Therefore, it is important to develop and test new drugs for RA that specifically target inflamed/swollen joints and simultaneously attenuate other possible damages to healthy tissues. Nanotechnology can be a good alternative to consider when envisioning precise medication for treating RA. Through the use of nanoparticles, it is possible to increase bioavailability and bioactivity of therapeutics and enable selective targeting to damaged joints. Herein, recent studies using nanoparticles for the treatment of RA, namely with liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles, have been reviewed. These therapeutic strategies have shown great promise in improving the treatment over that by traditional drugs. The results of these studies confirm that feasibility of the use of nanoparticles is mainly due to their biocompatibility, low toxicity, controlled release, and selective drug delivery to inflamed tissues in animal RA models. Therefore, it is possible to claim that nanotechnology will, in the near future, play a crucial role in advanced treatments and patient-specific therapies for human diseases such as RA. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-04 2018-04-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1822/56681 |
url |
http://hdl.handle.net/1822/56681 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Oliveira I. M., Gonçalves C., Reis R. L., Oliveira J. M. Engineering nanoparticles for targeting rheumatoidarthritis: Past, present, and future trends, Nano Research, Vol. 11, Issue 9, pp. 1-18, doi:10.1007/s12274-018-2071-3, 2018 1998-0124 10.1007/s12274-018-2071-3 https://link.springer.com/article/10.1007%2Fs12274-018-2071-3 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Tsinghua University Press |
publisher.none.fl_str_mv |
Tsinghua University Press |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799132605411491840 |